Pierian Biosciences opens second Liverpool laboratory in six months

The scaling diagnostic development and laboratory service provider expands their UK operations, bringing LSP’s lab occupancy to 100%.

Having launched its first permanent UK Laboratory in October 2022 at Liverpool Science Park (LSP), Pierian Biosciences has now signed a lease for a second CAT-2 laboratory within the Sciontec Developments Limited (Sciontec) owned innovation centre.

Now occupying 1,500sq ft of lab and office space at LSP, the Nashville-headquartered personalised medicine and translational science developer is able to increase their provision of clinically actionable diagnostic information, enabling healthcare providers to personalise treatment of patients with cancer and auto-immune diseases.

Norman Purvis, Chief Scientific Officer, Head of Research and Development at Pierian Biosciences, said: “Following our positive landing at Liverpool Science Park last year, we are excited to be expanding our footprint within the Knowledge Quarter Liverpool innovation district, and are progressing discussions with collaborators and partners to move our goal of enabling treatment directing Personal Medicine for Oncology and Immunotherapies closer to the finish line.

“The opening of our second Liverpool laboratory has provided additional space for us to grow into and create new employment opportunities as our UK team expands, and we are grateful to the entire team at Sciontec who have helped facilitate this latest phase of our growth strategy.”

George Barclay, Head of Property, FM and Operations at Sciontec, added: “We are delighted that Pierian Biosciences has been able to scale-up so quickly here at Liverpool Science Park. Sciontec prides itself on providing great spaces for great minds, and this expansion deal is testament to that.

“Our innovation centres also offer unrivalled connectivity and collaboration opportunities with local academic institutions and oncology specialists, and will provide the ideal base for Pierian Biosciences to expand even further within, over the coming years.”

Sciontec has experienced strong growth across its lab based customer portfolio at LSP this year, with Nano Biosols, Gemini Biosciences and ShimyaTech also recently renewing their leases.

Pierian Biosciences’ latest expansion has resulted in Liverpool Science Park’s lab space provision running at maximum capacity, with 100% of its laboratories being occupied.